Transaction DateRecipientSharesTypePriceValue
1st March 2021Fund V, L.P. Omega600Open or private sale$47.12$28,272.00
1st March 2021Fund V, L.P. Omega3,772Open or private sale$45.49$171,588.28
1st March 2021Fund V, L.P. Omega2,692Open or private sale$46.28$124,585.76
26th February 2021Fund V, L.P. Omega2,376Open or private sale$32.87$78,099.12
26th February 2021Fund V, L.P. Omega5,458Open or private sale$34.28$187,100.24
26th February 2021Fund V, L.P. Omega3,604Open or private sale$35.93$129,491.72
26th February 2021Fund V, L.P. Omega7,808Open or private sale$35.27$275,388.16
25th February 2021Fund V, L.P. Omega242Open or private sale$35.32$8,547.44
25th February 2021Fund V, L.P. Omega2,013Open or private sale$34.39$69,227.07
25th February 2021Fund V, L.P. Omega7,424Open or private sale$33.46$248,407.04
Trevi Therapeutics
Trevi Therapeutics logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.


Trevi Therapeutics, Inc. is a clinical stage biopharmaceutical company. It focuses on the formulation of nalbuphine ER, which use to treat chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in Parkinson's disease.


Ticker: TRVI
Sector: Healthcare
Industry: Biotechnology
SEC Central Index Key (CIK): 1563880
Employees: 15
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals